徐州去哪个医院做四维彩超好徐州医院做四维彩超可以吗,徐州胃镜检查 一般多少钱,徐州三个月四维彩超,徐州肠镜检查那种好,徐州怀孕42天孕酮多少正常,徐州四维多少周开始做,徐州四维b超那个医院

WASHINGTON, Dec. 7 (Xinhua) -- Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study published Wednesday in the Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.Aging-related memory loss is associated with the gradual deterioration of the structure and function of synapses (the connections between brain cells) in brain regions critical to learning and memory, such as the hippocampus.Recent studies suggested that histone acetylation, a chemical process that controls whether genes are turned on, affects this process. Specifically, it affects brain cells' ability to alter the strength and structure of their connections for information storage, a process known as synaptic plasticity, which is a cellular signature of memory.In the current study, Cui-Wei Xie, of the University of California, Los Angeles, and colleagues found that compared with younger rats, hippocampi from older rats have less brain-derived neurotrophic factor (BDNF) -- a protein that promotes synaptic plasticity -- and less histone acetylation of the Bdnf gene. By treating the hippocampal tissue from older animals with a drug that increased histone acetylation, they were able to restore BDNF production and synaptic plasticity to levels found in younger animals."These findings shed light on why synapses become less efficient and more vulnerable to impairment during aging," said Xie, who led the study. "Such knowledge could help develop new drugs for cognitive aging and aging-related neurodegenerative diseases, such as Alzheimer's disease," she added.

BEIJING, Jan. 12 (Xinhua) -- China's consumer price index (CPI), a main gauge of inflation, rose 4.1 percent year-on-year in December, down 0.1 percentage point from November on falling non-food prices, the National Bureau of Statistics (NBS) said Thursday.The CPI was up 5.4 percent in 2011 from the previous year, well above the government's full-year inflation control target of 4 percent, the NBS said in a statement on its website.The inflation rate in December marked a five-straight-month decline after hitting a 37-month high of 6.5 percent in July amid government tightening measures, according to the NBS data.On a monthly basis, the cost of living dipped 0.2 percent in December, while prices of entertainment, educational and cultural articles and services dropped 0.3 percent, the NBS said.Food prices, which account for nearly one third of the basket of goods in the nation's CPI calculation, went up 9.1 percent year-on-year in December and 1.2 percent month-on-month, the NBS said.The December inflation figure was in line with the market expectation, as many economists forecast that the CPI would grow around 4 percent year-on-year in December.China's Producer Price Index (PPI), a major measure of inflation at the wholesale level, rose 1.7 percent in December year-on-year, further weakening from 2.7 a month earlier.China has made controlling prices a top priority last year and implemented a series of measures to address the issue, including tightening monetary policy, cracking down on speculation, increasing food supplies and reducing circulation costs.

WASHINGTON, Nov. 8 (Xinhua) -- NASA plans to add an unmanned flight test of the Orion spacecraft in early 2014 to its contract with Lockheed Martin Space Systems for the multipurpose crew vehicle's design, development, test and evaluation, the U.S. space agency announced Tuesday.This test supports the new Space Launch System (SLS) that will take astronauts farther into space than ever before, and provide the cornerstone for America's future human spaceflight efforts."President Obama and Congress have laid out an ambitious space exploration plan, and NASA is moving out quickly to implement it," NASA Associate Administrator for Communications David Weaver said in a statement. "This flight test will provide invaluable data to support the deep space exploration missions this nation is embarking upon."Orion is part of the now defunct Constellation program canceled under President Barack Obama's 2011 budget proposal. Instead Obama urged NASA to work toward sending humans to an asteroid and then on to Mars -- and NASA says it wants to go ahead with that as quickly as possible.This Exploration Flight Test, or EFT-1, will fly two orbits to a high-apogee, with a high-energy re-entry through Earth's atmosphere. Orion will make a water landing and be recovered using operations planned for future human exploration missions. The test mission will be launched from Cape Canaveral to acquire critical re-entry flight performance data and demonstrate early integration capabilities that benefit the Orion, SLS."The entry part of the test will produce data needed to develop a spacecraft capable of surviving speeds greater than 20,000 mph and safely return astronauts from beyond Earth orbit," Associate Administrator for Human Exploration and Operations William Gerstenmaier said. "This test is very important to the detailed design process in terms of the data we expect to receive."

BEIJING, Jan. 14 (Xinhua) -- A Spring Festival gala was held at the Great Hall of the People Saturday to entertain the country's military officers, soldiers and civilians.Representatives of officers and soldiers in the military units and armed police forces in Beijing as well as some Beijing residents attended the gala.President Hu Jintao and other top Chinese leaders including Wu Bangguo, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang were also present at the gala.Hu expressed greetings to the audience and extended his good wishes for them, ahead of the traditional Spring Festival, or the Chinese Lunar New Year, which falls on Jan. 23 this year.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.